A recent exploratory analysis of four different phase 3 trials from the clinical development programs of both subcutaneous and oral semaglutide [17], a glucagon like peptide-1 receptor agonist, showed that semaglutide reduced CRP compared to comparator drugs in individuals with type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.